CTS/$CTS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About CTS
CTS Corp operates in the electronics industry. The company is a manufacturer of Sensors, Electronic components, and Actuators. It designs, manufactures, and sells a broad line of sensors, electronic components, and actuators mainly to original equipment manufacturers (OEMs) for the aerospace and defense, industrial, information technology, medical, telecommunications, and transportation markets. Geographically, it derives a majority of its revenue from the United States and also has a presence in China, Singapore, the Czech Republic, Taiwan, Denmark, and other countries.
- Ticker
- $CTS
- Sector
- Digital Hardware
- Primary listing
- NYSE
- Employees
- 3,492
- Headquarters
- Lisle, United States
- Website
- www.ctscorp.com
CTS Metrics
BasicAdvanced
$1.6B
23.54
$2.39
1.03
$0.16
0.28%
Price and volume
Market cap
$1.6B
Beta
1.03
52-week high
$69.55
52-week low
$36.03
Average daily volume
237K
Dividend rate
$0.16
Financial strength
Current ratio
2.609
Quick ratio
1.878
Long term debt to equity
0.149
Total debt to equity
0.157
Dividend payout ratio (TTM)
6.66%
Interest coverage (TTM)
26.71%
Profitability
EBITDA (TTM)
126.762
Gross margin (TTM)
39.71%
Net profit margin (TTM)
12.37%
Operating margin (TTM)
16.25%
Effective tax rate (TTM)
24.62%
Revenue per employee (TTM)
$160,000
Management effectiveness
Return on assets (TTM)
7.27%
Return on equity (TTM)
12.43%
Valuation
Price to earnings (TTM)
23.538
Price to revenue (TTM)
2.88
Price to book
2.81
Price to tangible book (TTM)
7.28
Price to free cash flow (TTM)
17.777
Free cash flow yield (TTM)
5.63%
Free cash flow per share (TTM)
3.164
Dividend yield (TTM)
0.28%
Forward dividend yield
0.28%
Growth
Revenue change (TTM)
8.53%
Earnings per share change (TTM)
17.72%
3-year revenue growth (CAGR)
-1.22%
10-year revenue growth (CAGR)
4.05%
3-year earnings per share growth (CAGR)
9.73%
10-year earnings per share growth (CAGR)
34.96%
What the Analysts think about CTS
Analyst ratings (Buy, Hold, Sell) for CTS stock.
Analyst projections of the future price of CTS stock.
Bulls say / Bears say
Medical and industrial demand is helping CTS rely less on transport: diversified end-market sales rose 15% year on year in Q2 and reached 59% of revenue, with medical up 45% and industrial up 16%. (GlobeNewswire)
Q2 adjusted gross margin rose 270 basis points to 41.5% and adjusted EPS increased to $0.74; CTS also raised its 2026 sales and adjusted EPS guidance, signalling stronger earnings momentum. (GlobeNewswire)
Q2 bookings exceeded sales, with a 1.1 book-to-bill ratio overall, while CTS won $163 million of new transportation business. Those orders could support future revenue even as current transport sales are soft. (StockAnalysis)
Transportation sales fell 2% in Q2, and management expects global light-vehicle production to be flat to modestly down in 2026. That leaves a key end market exposed to weak vehicle demand and trade uncertainty. (GlobeNewswire, StockAnalysis)
Aerospace and defence sales fell 15% year on year in Q2 as government funding and contract awards arrived slowly. That makes near-term growth in the segment dependent on the timing of programme spending. (StockAnalysis)
Q2 adjusted EPS included about $0.07 of favourable foreign-exchange effects and a customer reimbursement. Management also flagged tariff and precious-metal cost pressures, which could make the record margin and earnings performance harder to sustain. (Earningscalls.dev)
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2026.
CTS Financial Performance
Revenues and expenses
CTS Earnings Performance
Company profitability
Upcoming events
CTS News
AllArticlesVideos
Funds containing CTS
AllUSDGBPEUR
Fund name | Fund size | $CTS weighting |
|---|---|---|
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.09% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.09% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.06% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.06% |
iShares MSCI World Small Cap$WSML | $9B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.